K W Tan1, F H Leenen. 1. Hypertension Unit, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Abstract
AIMS: To assess the persistence of the antihypertensive effect of the ACE-inhibitor perindopril after one missed dose. METHODS: After a placebo run-in period, 10 hypertensive patients were started on perindopril 4 mg once daily in the morning, increased to 8 mg once daily after 4 weeks if office diastolic BP >85 mmHg. 24 h BP monitoring was performed at the end of the placebo run-in period and during active treatment in week 9 and 10 on either active treatment or a placebo-day using a double-blind, randomized, cross-over design. RESULTS:Office BP decreased from 155+/-3/100+/-2 mmHg at the end of placebo to 139+/-3/89+/-2 mmHg (P<0.05 vs placebo) after 8 weeks of active treatment. After 2 months of active treatment, 24 h ABP showed significant decreases in day BP by -11+/-1/-7+/-1 mmHg and in night BP by -11+/-2/-7+/-1 mmHg while on active treatment. During the placebo-day, daytime BP showed decreases by -10+/-1/-5+/-1 and night BP by -8+/-2/-6+/-1 mmHg (NS vs active treatment day). CONCLUSIONS:Perindopril 4-8 mg day-1 causes a persistent decrease in BP during the 24 h dosing interval, which is mostly maintained over the 24-48 h after dosing.
RCT Entities:
AIMS: To assess the persistence of the antihypertensive effect of the ACE-inhibitor perindopril after one missed dose. METHODS: After a placebo run-in period, 10 hypertensivepatients were started on perindopril 4 mg once daily in the morning, increased to 8 mg once daily after 4 weeks if office diastolic BP >85 mmHg. 24 h BP monitoring was performed at the end of the placebo run-in period and during active treatment in week 9 and 10 on either active treatment or a placebo-day using a double-blind, randomized, cross-over design. RESULTS: Office BP decreased from 155+/-3/100+/-2 mmHg at the end of placebo to 139+/-3/89+/-2 mmHg (P<0.05 vs placebo) after 8 weeks of active treatment. After 2 months of active treatment, 24 h ABP showed significant decreases in day BP by -11+/-1/-7+/-1 mmHg and in night BP by -11+/-2/-7+/-1 mmHg while on active treatment. During the placebo-day, daytime BP showed decreases by -10+/-1/-5+/-1 and night BP by -8+/-2/-6+/-1 mmHg (NS vs active treatment day). CONCLUSIONS:Perindopril 4-8 mg day-1 causes a persistent decrease in BP during the 24 h dosing interval, which is mostly maintained over the 24-48 h after dosing.
Authors: F H Leenen; T W Wilson; P Bolli; P Larochelle; M Myers; S P Handa; G Boileau; J Tanner Journal: Can J Cardiol Date: 1997-10 Impact factor: 5.223
Authors: L Vaur; G Bobrie; C Dutrey-Dupagne; I Dubroca; B Vaisse; M B d'Yvoire; F Elkik; G Chatellier; J Menard Journal: Am J Hypertens Date: 1998-02 Impact factor: 2.689
Authors: C G Isles; L M Walker; G D Beevers; I Brown; H L Cameron; J Clarke; V Hawthorne; D Hole; A F Lever; J W Robertson Journal: J Hypertens Date: 1986-04 Impact factor: 4.844